ANI Pharmaceuticals, Inc. (ANIP)
USD 65.32
(-3.27%)
USD 65.32
(-3.27%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 309.66 Million USD | 8.4% |
| 2022 | 285.66 Million USD | -0.3% |
| 2021 | 286.52 Million USD | 66.15% |
| 2020 | 172.44 Million USD | -1.91% |
| 2019 | 175.8 Million USD | 161.25% |
| 2018 | 67.29 Million USD | -66.04% |
| 2017 | 198.15 Million USD | 64.25% |
| 2016 | 120.64 Million USD | 6.36% |
| 2015 | 113.42 Million USD | 2.47% |
| 2014 | 110.69 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | -100.0% |
| 2011 | 17.33 Million USD | -0.57% |
| 2010 | 17.43 Million USD | 4.56% |
| 2009 | 16.67 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 309.24 Million USD | -8.1% |
| 2024 Q1 | 309.45 Million USD | 8.65% |
| 2023 Q4 | 309.66 Million USD | 8.64% |
| 2023 Q3 | 285.03 Million USD | -0.07% |
| 2023 FY | 309.66 Million USD | 8.4% |
| 2023 Q1 | 285.45 Million USD | -0.07% |
| 2023 Q2 | 285.24 Million USD | -0.07% |
| 2022 Q3 | 285.88 Million USD | -0.07% |
| 2022 FY | 285.66 Million USD | -0.3% |
| 2022 Q1 | 286.3 Million USD | -0.07% |
| 2022 Q2 | 286.09 Million USD | -0.07% |
| 2022 Q4 | 285.66 Million USD | -0.07% |
| 2021 Q4 | 286.52 Million USD | 53.99% |
| 2021 FY | 286.52 Million USD | 66.15% |
| 2021 Q3 | 186.06 Million USD | -1.83% |
| 2021 Q2 | 189.52 Million USD | 12.15% |
| 2021 Q1 | 168.98 Million USD | -2.01% |
| 2020 Q2 | 177.87 Million USD | -5.43% |
| 2020 Q4 | 172.44 Million USD | -1.55% |
| 2020 Q3 | 175.16 Million USD | -1.53% |
| 2020 FY | 172.44 Million USD | -1.91% |
| 2020 Q1 | 188.09 Million USD | 6.99% |
| 2019 Q4 | 175.8 Million USD | 171.0% |
| 2019 FY | 175.8 Million USD | 161.25% |
| 2019 Q2 | 65.68 Million USD | -1.22% |
| 2019 Q1 | 66.5 Million USD | -1.18% |
| 2019 Q3 | 64.87 Million USD | -1.24% |
| 2018 Q2 | 199.38 Million USD | 0.33% |
| 2018 FY | 67.29 Million USD | -66.04% |
| 2018 Q4 | 67.29 Million USD | -66.36% |
| 2018 Q3 | 200.07 Million USD | 0.34% |
| 2018 Q1 | 198.72 Million USD | 0.29% |
| 2017 FY | 198.15 Million USD | 64.25% |
| 2017 Q4 | 198.15 Million USD | 30.98% |
| 2017 Q3 | 151.28 Million USD | -2.01% |
| 2017 Q2 | 154.38 Million USD | 1.23% |
| 2017 Q1 | 152.5 Million USD | 26.41% |
| 2016 Q4 | 120.64 Million USD | 1.54% |
| 2016 Q2 | 116.99 Million USD | 1.56% |
| 2016 FY | 120.64 Million USD | 6.36% |
| 2016 Q1 | 115.19 Million USD | 1.56% |
| 2016 Q3 | 118.8 Million USD | 1.55% |
| 2015 FY | 113.42 Million USD | 2.47% |
| 2015 Q1 | 112.17 Million USD | 1.34% |
| 2015 Q4 | 113.42 Million USD | -1.53% |
| 2015 Q3 | 115.19 Million USD | 1.34% |
| 2015 Q2 | 113.67 Million USD | 1.34% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | 110.69 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 110.69 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q1 | 10.49 Million USD | -39.47% |
| 2012 FY | - USD | -100.0% |
| 2012 Q2 | 10.47 Million USD | -0.15% |
| 2012 Q3 | 7.59 Million USD | -27.53% |
| 2011 FY | 17.33 Million USD | -0.57% |
| 2011 Q4 | 17.33 Million USD | -9.9% |
| 2011 Q3 | 19.24 Million USD | -2.58% |
| 2011 Q2 | 19.75 Million USD | 9.51% |
| 2011 Q1 | 18.03 Million USD | 3.44% |
| 2010 Q3 | 18.36 Million USD | -0.56% |
| 2010 Q1 | 18.08 Million USD | 8.45% |
| 2010 FY | 17.43 Million USD | 4.56% |
| 2010 Q2 | 18.46 Million USD | 2.11% |
| 2010 Q4 | 17.43 Million USD | -5.05% |
| 2009 FY | 16.67 Million USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | 16.67 Million USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -10102.116% |
| Safety Shot Inc | 304.9 Thousand USD | -101461.788% |
| Bright Green Corporation | 201.78 Thousand USD | -153366.348% |
| Embecta Corp. | 1.62 Billion USD | 80.948% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -240.012% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 36.797% |
| Dynavax Technologies Corporation | 252.41 Million USD | -22.681% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 38.257% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -2223.796% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 39.729% |
| PainReform Ltd. | 30 Thousand USD | -1032130.0% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -57348.774% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -57348.774% |
| SCYNEXIS, Inc. | 12.15 Million USD | -2446.83% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -264282.86% |
| Journey Medical Corporation | 14.62 Million USD | -2017.829% |
| Alpha Teknova, Inc. | 13.25 Million USD | -2236.948% |
| Procaps Group, S.A. | 28.41 Million USD | -990.0% |
| Theratechnologies Inc. | 51.26 Million USD | -504.103% |
| Harrow Health, Inc. | 183.17 Million USD | -69.059% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -355841.379% |
| Biofrontera Inc. | 804 Thousand USD | -38416.045% |
| DURECT Corporation | 2.7 Million USD | -11360.733% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -832.85% |
| Cronos Group Inc. | 1.55 Million USD | -19763.31% |
| OptiNose, Inc. | 611 Thousand USD | -50582.324% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 37.856% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -805.73% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -67959.121% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -409.785% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -2322.29% |
| Radius Health, Inc. | 339.66 Million USD | 8.831% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -2918.805% |
| Phibro Animal Health Corporation | 458.28 Million USD | 32.429% |
| Procaps Group S.A. | 28.41 Million USD | -990.0% |
| Alvotech | 1.02 Billion USD | 69.87% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -4640.799% |
| Viatris Inc. | 16.18 Billion USD | 98.087% |
| Rockwell Medical, Inc. | 8.29 Million USD | -3634.101% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -2747.007% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -92065.862% |
| Tilray Brands, Inc. | 287.93 Million USD | -7.548% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -156.965% |
| Shineco, Inc. | 10.01 Million USD | -2991.332% |
| PetIQ, Inc. | 437.82 Million USD | 29.27% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -147361.429% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -19.887% |
| Alimera Sciences, Inc. | 64.48 Million USD | -380.189% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -704.043% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -229133.32% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -4415.861% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -42909.583% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1377186.07% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -845.266% |
| Hempacco Co., Inc. | 5.93 Million USD | -5121.193% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 69.87% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -450.856% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 49.739% |
| Currenc Group, Inc. | 2.5 Million USD | -12252.302% |
| Kamada Ltd. | 7.43 Million USD | -4063.337% |
| Indivior PLC | 235.66 Million USD | -31.401% |
| Evoke Pharma, Inc. | 5 Million USD | -6093.38% |
| Flora Growth Corp. | 942 Thousand USD | -32773.567% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -1377186.07% |
| Evolus, Inc. | 120.35 Million USD | -157.288% |
| HUTCHMED (China) Limited | 48.18 Million USD | -542.613% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 47.442% |
| Akanda Corp. | 2.49 Million USD | -12300.872% |